Benjamin P. Saylor

North Olmsted

Content Managing Editor at Urology Times

Featured in: Favicon

urologytimes.com Favicon

modernmedicine.com Favicon

onclive.com Favicon

curetoday.com Favicon

targetedonc.com Favicon

oncnursingnews.com Favicon

newsbreak.com Favicon

diagnosticimaging.com

Articles

NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

6 days ago | urologytimes.com | Benjamin P. Saylor

Findings of an exploratory analysis of the phase 3 NIAGARA trial (NCT03732677) evaluating perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy (NAC) with radical cystectomy vs NAC with radical cystectomy alone appear to support the utility of circulating tumor DNA (ctDNA) as a biomarker in the neoadjuvant setting.1 The findings also lend further credence to this muscle-invasive bladder cancer treatment regimen, investigators reported at the 2025 American Society of Clinical...
Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC

6 days ago | urologytimes.com | Benjamin P. Saylor

For patients with untreated unresectable or metastatic urothelial carcinoma who are not eligible for cisplatin, combination nivolumab (Opdivo) plus ipilimumab (Yervoy) did not achieve statistical significance for the end point of overall survival (OS), according to data from the phase 3 CheckMate 901 trial (NCT03036098).1 However, the treatment combination did show a notable duration of response and “favorable landmark OS after 12 months,” according to Michiel Van der Heijden, MD, PhD,...
EFS benefit is seen with sasanlimab in CIS and T1 NMIBC

1 week ago | urologytimes.com | Benjamin P. Saylor

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found that the treatment combination improved event-free survival (EFS) in patients with carcinoma in situ (CIS) and T1 tumors.1The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, by Thomas B.
Interim ENLIGHTED data show promise padeliporfin VTP therapy in UTUC

1 week ago | urologytimes.com | Benjamin P. Saylor

Data from an interim analysis of the phase 3 ENLIGHTED trial indicate that padeliporfin vascular targeted photodynamic (VTP) therapy is safe and effective for the treatment of low-grade upper tract urothelial cancer.1“This treatment is efficacious, at least in this interim analysis. It does have an excellent safety profile. Recruitment will continue and hopefully will result in approval,” said presenting author Vitaly Margulis, MD, the Paul C.
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

1 week ago | urologytimes.com | Benjamin P. Saylor

Results of the EORTC-GUCG 1333/PEACE-3 (NCT02194842) trial were published in the Annals of Oncology today, May 30, 2025, demonstrating that combination enzalutamide (Xtandi) plus radium-223 (Ra223, Xofigo) for the treatment of metastatic castration-resistant prostate cancer with bone metastases is both safe and associated with significantly improved radiological progression-free survival (rPFS).1,2 Specifically, investigators reported that the addition of Ra223 to enzalutamide was associated...
Study results affirm effectiveness of evolving prostate cancer therapies

3 weeks ago | urologytimes.com | Stephen J. Freedland |Benjamin P. Saylor

In a recent interview with Urology Times®, Stephen J. Freedland, MD, discussed the findings from a recent study comparing randomized controlled trials and real-world efficacy of prostate cancer treatments.1 The study compared the outcomes of drugs approved between 2010 and 2019.
Expert discusses genitourinary syndrome of menopause guidelines

3 weeks ago | urologytimes.com | Karyn S. Eilber |Benjamin P. Saylor

The recent release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction]/[American Urogynecologic Society] Guideline” has been met with praise by health care professionals. Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for genitourinary syndrome of menopause (GSM).
Durvalumab plus BCG significantly improves DFS in NMIBC

4 weeks ago | urologytimes.com | Benjamin P. Saylor |Hannah Clarke

Treatment for 1 year with durvalumab (Imfinzi) plus standard-of-care BCG induction and maintenance therapy was associated with a statistically significant and clinically meaningful improvement in disease-free survival (DFS) high-risk non–muscle invasive bladder cancer (NMIBC) vs BCG induction and maintenance alone, AstraZeneca announced.1 According to the company, although the phase 3 POTOMAC trial (NCT03528694) was statistically powered to formally evaluate overall survival, “a descriptive...
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world

1 month ago | urologytimes.com | Stephen J. Freedland |Benjamin P. Saylor

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments.1 Investigators found that benefits of treatments that are observed in trials also appear in the real world. In a recent interview with Urology Times®, study author Stephen J. Freedland, MD, discussed the findings, one of which was that real-world overall survival gains appeared to increase with the duration a new therapy was on the market.
Expert discusses the NMIBC trials landscape

1 month ago | urologytimes.com | Joshua J. Meeks |Benjamin P. Saylor

In a recent interview with Urology Times®, Joshua J. Meeks, MD, PhD, shared his thoughts on some of the notable ongoing trials in the non–muscle invasive bladder cancer (NMIBC) space and what urologists should be on the look-out for. “For a NMIBC, all you have to do is look forward to the metastatic setting.